Safety and Duration of Effect of 40-Unit PrabotulinumtoxinA-xvfs for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients: A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled Trial
Aesthetic Surgery Journal · 20.08.2024 · 44 (9) · 987-1000
DOI: 10.1093/asj/sjae051 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 20.03.2024. Verfasst von Steven Fagien und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Skin Aging, Forehead. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Evolus, Inc, Evolus.
Abstract (Originalsprache)
Background
Extending the duration of effect of botulinum toxins—by administering doses beyond those of the approved labels—has been an area of increasing interest in the field of aesthetics.
Objectives
The aim of this study was to investigate the safety and duration of effect of 40-unit (U) prabotulinumtoxinA-xvfs (twice the approved dose and concentration) for the treatment of moderate-to-severe glabellar lines.
Methods
A total of 154 adult patients were randomized 1:1:1 to a single treatment of either 40 U prabotulinumtoxinA-xvfs (PRA 40, 5 injections of 8 U/0.05 mL), or 20 U of either prabotulinumtoxinA-xvfs (PRA 20) or onabotulinumtoxinA (ONA 20). Both 20-U controls were administered as 5 injections of 4 U/0.1 mL. Efficacy and safety were assessed on days 2, 7 (by telephone), 30, and every 30 days thereafter up to 365 days or until the patient had returned to baseline. The primary effectiveness endpoint was the duration of effect (estimated by Kaplan-Meier analysis), defined as the number of days from treatment day (baseline) to the day that glabellar line severity at maximum frown by investigator assessment returned to the baseline value.
Results
Patients had a mean age of 47 years (20-72 years); 69.5% had severe glabellar lines at baseline. Of the 36 adverse events, 32 (88.9%) were mild and 4 (11.1%) were moderate in severity; none were serious. The median durations of effect were estimated to be 183, 149, and 148 days for PRA 40–, PRA 20–, and ONA 20–treated patients, respectively.
Conclusions
In this phase 2 pilot study, 40 U prabotulinumtoxinA-xvfs was observed to be safe and had a duration of 6 months. Level of Evidence: 1
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Förderung
- Evolus, Inc
- Evolus
Zitieren
APA
Fagien, S., Avelar, R. L., Cox, S. E., Joseph, J. H., Kaufman-Janette, J., & Marcus, K. A. (2024). Safety and Duration of Effect of 40-Unit PrabotulinumtoxinA-xvfs for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients: A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled Trial. Aesthetic Surgery Journal, 44(9), 987-1000. https://doi.org/10.1093/asj/sjae051
Vancouver
Fagien S, Avelar RL, Cox SE, Joseph JH, Kaufman-Janette J, Marcus KA. Safety and Duration of Effect of 40-Unit PrabotulinumtoxinA-xvfs for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients: A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled Trial. Aesthetic Surgery Journal. 2024;44(9):987-1000. doi:10.1093/asj/sjae051
BibTeX
@article{Fagien2024,
author = {Fagien, Steven and Avelar, Rui L and Cox, Sue Ellen and Joseph, John H and Kaufman-Janette, Joely and Marcus, Keith A},
title = {Safety and Duration of Effect of 40-Unit PrabotulinumtoxinA-xvfs for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients: A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled Trial},
journal = {Aesthetic Surgery Journal},
year = {2024},
volume = {44},
number = {9},
pages = {987--1000},
doi = {10.1093/asj/sjae051}
}
EUVIMED